Vanguard's 2 New Muni ETFs Have an Advantage Over Mutual Funds
Vanguard rounded out its municipal bond fund suite last week with a pair of passively managed tax-exempt funds: the Long-Term Tax-Exempt Bond and New York Tax-Exempt Bond ETFs. The strategies are new, not replicating existing mutual funds from the company's extensive product line. There are, however, two active mutual funds in the same category, the Admiral shares of which charge 9 basis points — the same fee charged by the passive ETFs. But there is still a draw for index-level returns, or beta.
'Some clients just want the beta,' along with the low cost and ease of operation with an ETF, said Perryne Desai, senior fixed income product manager for the two new funds. 'Now that bonds are actually yielding something and they are a safe harbor … there is no better time to be in fixed income. There's no better time to be in munis.'
This story was originally published on The Daily Upside. To receive exclusive news and analysis of the rapidly evolving ETF landscape, built for advisors and capital allocators, subscribe to our free ETF Upside newsletter.
Vanguard has been building out its muni bond ETF line for two years, Jeff DeMaso, editor of The Independent Vanguard Adviser, said in a statement about the launch. With the additions, Vanguard has two dozen muni mutual funds and ETFs. The two new products 'won't turn heads but are practical additions to Vanguard's roster,' DeMaso said. And they don't necessarily offer a cost advantage over two existing active mutual funds, unless one takes into account the $50,000 minimum needed for Vanguard's Admiral shares — the Investor shares, which have a $3,000 minimum, charge 17 basis points for the Long-Term and 14 for the New York version. 'If you are willing to own a mutual fund (over an ETF), you can get Vanguard's active management for free,' DeMaso said. 'That's a good deal in my book.'
Some of the details about the active funds:
The Long-Term Tax-Exempt Fund, at $16.9 billion, has trailing returns of 0.26% over a year, 2.9% over three years, and 0.76% over five years, data from Morningstar show.
The New York Long-Term Tax-Exempt Fund, at $5.1 billion, returned 0.28% over a year, 3.04% over three years, and 0.73% over five.
Better for the Beta: The new ETFs are managed by Vanguard's fixed income group, whose track record in active management benefits the index team, Desai said, citing the example of the nearly 10-year-old Tax-Exempt Bond ETF, which has a beta of 0.97, according to Morningstar. 'Our tracking error is pretty darn tight, and in municipals, that's difficult to accomplish.'
The post Vanguard's 2 New Muni ETFs Have an Advantage Over Mutual Funds appeared first on The Daily Upside.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...
Exploring the Latest Investment Strategies of Vanguard Health Care Fund (Trades, Portfolio) Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the second quarter of 2025, shedding light on its strategic investment decisions during this period. Managed by Jean M. Hynes, CFA, CEO of Wellington Management Company, the fund is renowned for its focus on long-term capital appreciation within the health care sector. Wellington Management Company, established in 1928, is one of the oldest and most respected institutional investment managers in the United States, advising the Vanguard Health Care Fund (Trades, Portfolio) since 1984. The fund aims to maintain a diversified exposure across five primary subsectors: health services, medical products, specialty pharmaceuticals, major pharmaceuticals, and international markets. Its investment philosophy emphasizes companies with robust balance sheets, strong management, and potential for innovative products that could drive above-average growth in revenue and earnings. The fund's contrarian style often leads to purchasing stocks after negative events have caused a decline in share price. Summary of New Buy Vanguard Health Care Fund (Trades, Portfolio) added a total of eight stocks, with the most significant addition being Johnson & Johnson (NYSE:JNJ). The fund acquired 4,660,244 shares, which now account for 2.05% of the portfolio, with a total value of $711.85 million. The second largest addition was Roche Holding AG (XSWX:ROG), consisting of 1,677,044 shares, representing approximately 1.58% of the portfolio, with a total value of CHF 547,420,130. The third largest addition was Gilead Sciences Inc (NASDAQ:GILD), with 4,823,087 shares, accounting for 1.54% of the portfolio and a total value of $534.74 million. Key Position Increases Vanguard Health Care Fund (Trades, Portfolio) also increased stakes in a total of 16 stocks. The most notable increase was in Elevance Health Inc (NYSE:ELV), with an additional 507,005 shares, bringing the total to 1,700,286 shares. This adjustment represents a significant 42.49% increase in share count, a 0.57% impact on the current portfolio, with a total value of $661.34 million. The second largest increase was in Cencora Inc (NYSE:COR), with an additional 501,886 shares, bringing the total to 2,279,215. This adjustment represents a significant 28.24% increase in share count, with a total value of $683.42 million. Summary of Sold Out Vanguard Health Care Fund (Trades, Portfolio) completely exited 12 holdings in the second quarter of 2025. Notable exits include Blueprint Medicines Corp (BPMC), where the fund sold all 1,362,970 shares, resulting in a -0.32% impact on the portfolio. Another significant exit was Surgery Partners Inc (NASDAQ:SGRY), with the liquidation of all 4,602,252 shares, causing a -0.29% impact on the portfolio. Key Position Reduces Vanguard Health Care Fund (Trades, Portfolio) also reduced its position in 45 stocks. The most significant changes include a reduction in Novartis AG (XSWX:NOVN) by 5,691,220 shares, resulting in a -49.44% decrease in shares and a -1.66% impact on the portfolio. The stock traded at an average price of CHF 93.19 during the quarter and has returned 8.24% over the past three months and 13.88% year-to-date. Another notable reduction was in Edwards Lifesciences Corp (NYSE:EW) by 6,663,224 shares, resulting in a -37.32% reduction in shares and a -1.27% impact on the portfolio. The stock traded at an average price of $74.55 during the quarter and has returned 2.89% over the past three months and 4.93% year-to-date. Portfolio Overview As of the second quarter of 2025, Vanguard Health Care Fund (Trades, Portfolio)'s portfolio included 81 stocks. The top holdings included 10.78% in Eli Lilly and Co (NYSE:LLY), 6.49% in AstraZeneca PLC (LSE:AZN), 5.56% in UnitedHealth Group Inc (NYSE:UNH), 4.52% in Merck & Co Inc (NYSE:MRK), and 4.35% in Boston Scientific Corp (NYSE:BSX). The holdings are mainly concentrated in one of the 11 industries: Healthcare. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus.
Yahoo
3 hours ago
- Yahoo
Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...
Exploring the Latest Investment Strategies of Vanguard Health Care Fund (Trades, Portfolio) Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the second quarter of 2025, shedding light on its strategic investment decisions during this period. Managed by Jean M. Hynes, CFA, CEO of Wellington Management Company, the fund is renowned for its focus on long-term capital appreciation within the health care sector. Wellington Management Company, established in 1928, is one of the oldest and most respected institutional investment managers in the United States, advising the Vanguard Health Care Fund (Trades, Portfolio) since 1984. The fund aims to maintain a diversified exposure across five primary subsectors: health services, medical products, specialty pharmaceuticals, major pharmaceuticals, and international markets. Its investment philosophy emphasizes companies with robust balance sheets, strong management, and potential for innovative products that could drive above-average growth in revenue and earnings. The fund's contrarian style often leads to purchasing stocks after negative events have caused a decline in share price. Summary of New Buy Vanguard Health Care Fund (Trades, Portfolio) added a total of eight stocks, with the most significant addition being Johnson & Johnson (NYSE:JNJ). The fund acquired 4,660,244 shares, which now account for 2.05% of the portfolio, with a total value of $711.85 million. The second largest addition was Roche Holding AG (XSWX:ROG), consisting of 1,677,044 shares, representing approximately 1.58% of the portfolio, with a total value of CHF 547,420,130. The third largest addition was Gilead Sciences Inc (NASDAQ:GILD), with 4,823,087 shares, accounting for 1.54% of the portfolio and a total value of $534.74 million. Key Position Increases Vanguard Health Care Fund (Trades, Portfolio) also increased stakes in a total of 16 stocks. The most notable increase was in Elevance Health Inc (NYSE:ELV), with an additional 507,005 shares, bringing the total to 1,700,286 shares. This adjustment represents a significant 42.49% increase in share count, a 0.57% impact on the current portfolio, with a total value of $661.34 million. The second largest increase was in Cencora Inc (NYSE:COR), with an additional 501,886 shares, bringing the total to 2,279,215. This adjustment represents a significant 28.24% increase in share count, with a total value of $683.42 million. Summary of Sold Out Vanguard Health Care Fund (Trades, Portfolio) completely exited 12 holdings in the second quarter of 2025. Notable exits include Blueprint Medicines Corp (BPMC), where the fund sold all 1,362,970 shares, resulting in a -0.32% impact on the portfolio. Another significant exit was Surgery Partners Inc (NASDAQ:SGRY), with the liquidation of all 4,602,252 shares, causing a -0.29% impact on the portfolio. Key Position Reduces Vanguard Health Care Fund (Trades, Portfolio) also reduced its position in 45 stocks. The most significant changes include a reduction in Novartis AG (XSWX:NOVN) by 5,691,220 shares, resulting in a -49.44% decrease in shares and a -1.66% impact on the portfolio. The stock traded at an average price of CHF 93.19 during the quarter and has returned 8.24% over the past three months and 13.88% year-to-date. Another notable reduction was in Edwards Lifesciences Corp (NYSE:EW) by 6,663,224 shares, resulting in a -37.32% reduction in shares and a -1.27% impact on the portfolio. The stock traded at an average price of $74.55 during the quarter and has returned 2.89% over the past three months and 4.93% year-to-date. Portfolio Overview As of the second quarter of 2025, Vanguard Health Care Fund (Trades, Portfolio)'s portfolio included 81 stocks. The top holdings included 10.78% in Eli Lilly and Co (NYSE:LLY), 6.49% in AstraZeneca PLC (LSE:AZN), 5.56% in UnitedHealth Group Inc (NYSE:UNH), 4.52% in Merck & Co Inc (NYSE:MRK), and 4.35% in Boston Scientific Corp (NYSE:BSX). The holdings are mainly concentrated in one of the 11 industries: Healthcare. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus. Sign in to access your portfolio


The Hill
10 hours ago
- The Hill
Inside Trump's move to oust Billy Long
Multiple sources familiar with the matter told The Hill that leadership at the Treasury Department clashed with Long and that there were concerns within the administration that he was not a good fit to lead an agency that prides itself on implementing tax policy without getting caught up in partisan drama. But his exit also means the Internal Revenue Service (IRS) will have its seventh commissioner of the calendar year, with Treasury Secretary Scott Bessent taking over on an interim basis. 'I think they're going through turbulence right now,' one source familiar with the matter told The Hill. 'People just don't know yet what the future holds.' Long was a controversial choice to lead the IRS, a technocratic agency responsible for collecting tax revenue and enforcing the nation's tax laws. A former Republican Congress member from Missouri, Long previously worked as an auctioneer and a real estate broker. He drew scrutiny over his promotion of a pandemic-era tax credit that was riddled with fraudulent claims. Sources told The Hill that there was growing frustration among Treasury officials with IRS leadership since Long's arrival as commissioner. One source familiar with the matter said Long had gone off-script and made remarks that required clarifications or cleaning up, something viewed as a particular issue on an issue as sensitive as taxes. The Hill's Brett Samuels has more here.